Focused Wealth Management Inc increased its position in shares of Novartis AG (NYSE:NVS) by 29.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 868 shares of the company’s stock after purchasing an additional 200 shares during the quarter. Focused Wealth Management Inc’s holdings in Novartis were worth $74,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. MAI Capital Management acquired a new stake in Novartis in the 4th quarter valued at about $472,000. LeJeune Puetz Investment Counsel LLC increased its position in Novartis by 5.6% in the 4th quarter. LeJeune Puetz Investment Counsel LLC now owns 6,256 shares of the company’s stock valued at $537,000 after acquiring an additional 331 shares in the last quarter. Dynamic Advisor Solutions LLC increased its position in Novartis by 6.8% in the 4th quarter. Dynamic Advisor Solutions LLC now owns 4,261 shares of the company’s stock valued at $366,000 after acquiring an additional 273 shares in the last quarter. Atlas Capital Advisors LLC increased its position in Novartis by 60.0% in the 4th quarter. Atlas Capital Advisors LLC now owns 6,399 shares of the company’s stock valued at $549,000 after acquiring an additional 2,399 shares in the last quarter. Finally, Advisor Partners LLC increased its position in Novartis by 40.9% in the 4th quarter. Advisor Partners LLC now owns 19,346 shares of the company’s stock valued at $1,660,000 after acquiring an additional 5,618 shares in the last quarter. Institutional investors and hedge funds own 11.17% of the company’s stock.

Several equities research analysts have recently commented on the stock. JPMorgan Chase & Co. reiterated a “sell” rating on shares of Novartis in a research report on Tuesday, January 29th. Credit Suisse Group cut shares of Novartis to a “sell” rating in a research report on Thursday, December 20th. Zacks Investment Research upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $96.00 price target for the company in a research report on Tuesday, December 18th. Jefferies Financial Group reiterated a “buy” rating and set a $105.00 price target on shares of Novartis in a research report on Tuesday, December 11th. Finally, Barclays cut shares of Novartis from an “equal weight” rating to a “sell” rating in a research report on Friday, December 7th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $90.94.

Shares of NYSE:NVS opened at $87.66 on Friday. Novartis AG has a one year low of $72.30 and a one year high of $92.39. The company has a quick ratio of 0.96, a current ratio of 1.20 and a debt-to-equity ratio of 0.29. The company has a market cap of $202.17 billion, a PE ratio of 17.22, a price-to-earnings-growth ratio of 1.91 and a beta of 0.69.

Novartis (NYSE:NVS) last released its quarterly earnings data on Wednesday, January 30th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.33 by ($0.09). Novartis had a return on equity of 15.83% and a net margin of 24.30%. The firm had revenue of $13.27 billion for the quarter, compared to the consensus estimate of $13.33 billion. During the same period in the previous year, the business earned $1.21 EPS. The firm’s revenue was up 2.7% compared to the same quarter last year. As a group, equities research analysts forecast that Novartis AG will post 5.43 earnings per share for the current fiscal year.

The company also recently disclosed an annual dividend, which will be paid on Wednesday, March 13th. Investors of record on Tuesday, March 5th will be paid a dividend of $2.8646 per share. This is a positive change from Novartis’s previous annual dividend of $2.33. The ex-dividend date is Monday, March 4th. This represents a yield of 3.27%. Novartis’s dividend payout ratio (DPR) is presently 37.52%.

TRADEMARK VIOLATION NOTICE: “Novartis AG (NVS) Position Raised by Focused Wealth Management Inc” was first posted by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.dailypolitical.com/2019/02/03/novartis-ag-nvs-position-raised-by-focused-wealth-management-inc.html.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Recommended Story: Buyback For Investors Defined

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.